These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25884485)

  • 21. Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using 32K BAC array.
    Mantripragada KK; Díaz de Ståhl T; Patridge C; Menzel U; Andersson R; Chuzhanova N; Kluwe L; Guha A; Mautner V; Dumanski JP; Upadhyaya M
    Genes Chromosomes Cancer; 2009 Oct; 48(10):897-907. PubMed ID: 19603524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
    Spurlock G; Knight SJ; Thomas N; Kiehl TR; Guha A; Upadhyaya M
    J Cancer Res Clin Oncol; 2010 Dec; 136(12):1869-80. PubMed ID: 20229272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1.
    McPherson JR; Ong CK; Ng CC; Rajasegaran V; Heng HL; Yu WS; Tan BK; Madhukumar P; Teo MC; Ngeow J; Thike AA; Rozen SG; Tan PH; Lee AS; Teh BT; Yap YS
    Cancer Med; 2015 Dec; 4(12):1871-8. PubMed ID: 26432421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.
    Park GH; Lee SJ; Yim H; Han JH; Kim HJ; Sohn YB; Ko JM; Jeong SY
    Oncol Rep; 2014 Oct; 32(4):1347-54. PubMed ID: 25109740
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis.
    Luscan A; Shackleford G; Masliah-Planchon J; Laurendeau I; Ortonne N; Varin J; Lallemand F; Leroy K; Dumaine V; Hivelin M; Borderie D; De Raedt T; Valeyrie-Allanore L; Larousserie F; Terris B; Lantieri L; Vidaud M; Vidaud D; Wolkenstein P; Parfait B; Bièche I; Massaad C; Pasmant E
    Clin Cancer Res; 2014 Jan; 20(2):358-71. PubMed ID: 24218515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.
    Mitchell DK; Burgess B; White EE; Smith AE; Sierra Potchanant EA; Mang H; Hickey BE; Lu Q; Qian S; Bessler W; Li X; Jiang L; Brewster K; Temm C; Horvai A; Albright EA; Fishel ML; Pratilas CA; Angus SP; Clapp DW; Rhodes SD
    Clin Cancer Res; 2024 Mar; 30(5):1038-1053. PubMed ID: 38127282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peripheral nerve sheath tumors from patients with neurofibromatosis type 1 do not have the chromosomal translocation t(X;18).
    Liew MA; Coffin CM; Fletcher JA; Hang MT; Tanito K; Niimura M; Viskochil D
    Pediatr Dev Pathol; 2002; 5(2):165-9. PubMed ID: 11910511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
    Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
    Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours.
    Bottillo I; Ahlquist T; Brekke H; Danielsen SA; van den Berg E; Mertens F; Lothe RA; Dallapiccola B
    J Pathol; 2009 Apr; 217(5):693-701. PubMed ID: 19142971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.
    Presneau N; Eskandarpour M; Shemais T; Henderson S; Halai D; Tirabosco R; Flanagan AM
    Br J Cancer; 2013 Mar; 108(4):964-72. PubMed ID: 23175151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular heterogeneity in malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1.
    Thomas L; Mautner VF; Cooper DN; Upadhyaya M
    Hum Genomics; 2012 Sep; 6(1):18. PubMed ID: 23244685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.
    Mattox AK; Douville C; Silliman N; Ptak J; Dobbyn L; Schaefer J; Popoli M; Blair C; Judge K; Pollard K; Pratilas C; Blakeley J; Rodriguez F; Papadopoulos N; Belzberg A; Bettegowda C
    Elife; 2022 Mar; 11():. PubMed ID: 35244537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells.
    Fischer-Huchzermeyer S; Dombrowski A; Hagel C; Mautner VF; Schittenhelm J; Harder A
    Am J Pathol; 2017 Jul; 187(7):1623-1632. PubMed ID: 28502478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs).
    Upadhyaya M; Spurlock G; Majounie E; Griffiths S; Forrester N; Baser M; Huson SM; Gareth Evans D; Ferner R
    Hum Mutat; 2006 Jul; 27(7):716. PubMed ID: 16786508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen's disease.
    Schmidt H; Taubert H; Meye A; Würl P; Bache M; Bartel F; Holzhausen HJ; Hinze R
    Cancer Lett; 2000 Jul; 155(2):181-90. PubMed ID: 10822134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
    Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study.
    Ferner RE; Golding JF; Smith M; Calonje E; Jan W; Sanjayanathan V; O'Doherty M
    Ann Oncol; 2008 Feb; 19(2):390-4. PubMed ID: 17932395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors. I. The role of tumor suppressor mutations.
    Carroll SL; Stonecypher MS
    J Neuropathol Exp Neurol; 2004 Nov; 63(11):1115-23. PubMed ID: 15581179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
    Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
    Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
    Salamon J; Mautner VF; Adam G; Derlin T
    Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.